Loading...
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for non-small cell lung cancer and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. On the other hand, it has been reported that a tumor c...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3583539/ https://ncbi.nlm.nih.gov/pubmed/22209766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2011.1614 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|